Further mechanisms related to host–tumor interactions and their influence on immune checkpoints resistance have been elucidated through the analysis of a cohort of longitudinal tissues from N = 56 melanoma patients treated with anti-CTLA-4 mAb and subsequently, upon progression, with anti-PD-1 mAb. This evidence concerns the gene CTLA4 and melanoma.